Back to Top
Go Back
Journal Photo for Annals of Oncology
Peer reviewed only Open Access

Annals of Oncology (AO)

Publisher : Elsevier
Oncology Medicine
Claim Your Journal Get PRC Visit Website
e-ISSN 1569-8041
p-ISSN 0923-7534
Issue Frequency Monthly
Impact Factor 50.5
Est. Year 1990
Mobile 31204853911
Country Netherlands The
Language English
APC YES
Impact Factor Assignee Google Scholar
Email annals1@esmo.org

Journal Descriptions

Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

Annals of Oncology (AO) is :-

  • International, Peer-Reviewed, Open Access, Refereed, Oncology, Medicine , Online or Print , Monthly Journal

  • UGC Approved, ISSN Approved: P-ISSN P-ISSN: 0923-7534, E-ISSN: 1569-8041, Established: 1990, Impact Factor: 50.5
  • Does Not Provide Crossref DOI

  • Indexed in: Scopus, PubMed

  • Not indexed in WoS, DOAJ, UGC CARE

Indexing

Publications of AO

119P - Role of immune checkpoint inhibitors in bone sarcomas and future aspects
SHUBHRA MEDHASHRI MISHRA November, 2019
Background The most common subtypes of bone sarcomas are osteosarcoma and Ewing sarcoma. They are rare and heterogeneous form of cancers of mainly mesenchymal origin. Neo-adjuvant chemother...
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
Bert Vogelstein August, 2015
Background Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA ...